medigraphic.com
Colegio de Medicina Interna de México.

2024, Number 7

<< Back Next >>

Med Int Mex 2024; 40 (7)

Glycemic control with basal insulins in hospitalized type 2 diabetics

Yamasaki RYH, Ramales MEM, Montaño EJÁ

Language: Spanish
References: 26
Page: 401-406
PDF size: 206.62 Kb.


ABSTRACT

Objective: To compare glycemic control with insulin glargine vs NPH in hospitalized type 2 diabetic patients.
Materials and Method: A quantitative, descriptive and observational, singlecenter research was carried out comparing mean glucose levels with glargine vs NPH in hospitalized patients.
Results: There were included 101 patients. Statistically significant differences were found at a 95% confidence level in favor of the glargine group. The difference in favor of glargine was -11.60 mg/dL of glucose reduction, providing greater glycemic control.
Conclusions: The use of insulin glargine compared to NPH insulin presented better glycemic control in patients, statistically significantly reducing the serum glucose value.


REFERENCES

  1. Pasquel F, Lansang C, Dhatariya K, et al. Management ofdiabetes and hyperglycaemia in the hospital. Lancet DiabetesEndocrinol 2021; 9: 174-88. https://doi.org/10.1016/S2213-8587(20)30381-8

  2. Manrique H, Gil F, Castillo L, et al. Manejo de las crisisglucémicas en pacientes adultos con diabetes mellitus:Guía de Práctica Clínica Basada en Evidencias. Rev Fac MedHum 2021; 21 (1): 50-64. DOI10.25176/RFMH.v21i1.3194

  3. American Diabetes Association. Standards of Medical Carein Diabetes. Diabetes Care 2023; 46: 14-20.

  4. Gloyn A, Drucker D. Precision medicine in the managementof type 2 diabetes. Lancet 2018; 6: 891-900. http://dx.doi.org/10.1016/S2213-8587(18)30052-4

  5. Semlitsch T, Engler J, Siebenhofer A, et al. (Ultra)long-actinginsulin analogues versus NPH insulin (human isophaneinsulin) for adults with type 2 diabetes mellitus. CochraneDatabase of Systematic Reviews 2020: CD005613. DOI:10.1002/14651858.CD005613.pub4

  6. Rodríguez E, Michahelles C. Long-acting insulin analoguesversus NPH insulin in type 2 diabetes mellitus. Rev Soc PeruMed Interna 2018; 31:104-109.

  7. Lipska K, Parker M, Moffet H, et al. Association of initiationof basal insulin analogs vs neutral protamine Hagedorninsulin with hypoglycemia-related emergency departmentvisits or hospital admissions and with glycemic control inpatients with type 2 diabetes. JAMA 2018; 320:53-62. doi:10.1001/jama.2018.7993

  8. Dlujnewsky I, García N, Medrano C, et al. Estudio Mauleactivo: Estudio comparativo entre niveles de hemoglobinaglicosilada entre insulina NPH vs insulina Glargina U100,en programa hospitalario durante 5 años en la región delMaule-Chile. Portales Medicos 2020; 15: 1072.

  9. Murphy C, Saliba L, MacDermott J, et al. Individualizingglycemic control in the critically ill. Critical CareNursing Quarterly 2020; 43: 14-27. DOI: 10.1097/CNQ.0000000000000288

  10. Patel V, Kuo E. Glycemic control in hospitalized strokepatients: A review. Curr Diab Rep 2021; 21. https://doi.org/10.1007/s11892-021-01416-1

  11. Pérez A, Ramos A, Carreras G. Insulin therapy in hospitalizedpatients. Am J Ther 2020; 27: e71-e78. DOI: 10.1097/MJT.0000000000001078

  12. Gert-Jan E, Steffen R, Dieter M. Accuracy of bloodglucose measurement and blood glucose targets.J Diabetes Sci Technol 2020; 14 (3): 553-559. DOI:10.1177/1932296820905581

  13. Cruz P. Inpatient hypoglycemia: The challenge remains. JDiabetes Sci Technol 2020; 4: 560-566. https://1d0o.i1.o1r7g/71/01.19137272/19963822906981280594180540

  14. Krinsley J, Rule P, Brownlee M, et al. Acute and chronicglucose control in critically ill patients with diabetes:The impact of prior insulin treatment. J DiabetesSci Technol 2021; 6: 483-495. DttOpsI://1d0o.i1.o1r7g/71/01.19137272/1996382291618023121203727277

  15. Wang H, Zhou Y, Zhai X, et al. Evaluating glycemic controlduring basalin or lantus administration in adults withcontrolled type 2 diabetes mellitus using continuous glucosemonitoring. Front Endocrinol 2021; 12: 754820. doi:10.3389/fendo.2021.754820

  16. Alhatem G, Aldiwani H, Alhatemi R, et al. Glycemic controlin the critically ill: Less is more. Cleveland Clinic J Med 2022;89: 4. doi:10.3949/ccjm.89a.20171

  17. Spanakis E, Urrutia A, Galindo R, et al. Continuous glucosemonitoring–guided insulin administration in hospitalizedpatients with diabetes: A randomized clinical trial. DiabetesCare 2022; 45: 2369-2375. https://doi.org/10.2337/dc22-0716

  18. Karter A, Parker M, Moffet H, et al. continuous glucosemonitor use prevents glycemic deterioration in insulintreatedpatients with type 2 diabetes. Diabetes TechnolTher 2022; 24: 5. DOI: 10.1089/dia.2021.0450

  19. Ran L, Li J, Bo Z. Effect of glycemic gap upon mortality incritically ill patients with diabetes. J Diabetes Investig 2021;12: 2212-2220. doi: 10.1111/jdi.13606

  20. Davis G, Galindo R, Migdal A, et al. Diabetes technologyin the inpatient setting for management of hyperglycemia.Endocrinol Metab Clin North Am 2020; 49 (1): 79-93.doi:10.1016/j.ecl.2019.11.002

  21. Sendekie A, Teshale A, Tefera Y. Glycemic control in newlyinsulin-initiated patients with type 2 diabetes mellitus: Aretrospective follow-up study at a university hospital inEthiopia. PLoS One 2022; 17 (5): e0268639. https://doi.org/10.1371/journal.pone.0268639

  22. Russo M, Marquez S, Elizondo C, et al. In-hospital mortalityand glycemic control in patients with hospital hyperglycemia.The review of DIABETIC STUDIES 2021; 7: 2. DOI10.1900/RDS.2021.17.50

  23. Gardner D, Shoback D. Greenspan Endocrinología básicay clínica. 10ª ed. Ciudad de México: McGraw-Hill, 2018.

  24. Courtney R, Tuttle N, Murphy J. NPH Insulin versus insulinglargine versus NPH insulin plus insulin glargine for thetreatment of dexamethasone-induced hyperglycemia inpatients with COVID-19: A retrospective cohort study. JPharmacy Technol 2023; 39 (2): 68-74. DttOpsI://1d0oi..1o1rg7/710/8.1715757/1827255122321512351613526932

  25. Lau E, Salem A, Chan J, et al. Insulin glargine comparedto neutral protamine Hagedorn (NPH) insulin in patientswith type-2 diabetes uncontrolled with oral anti-diabeticagents alone in Hong Kong: a cost-effectiveness analysis.Cost Eff Resour Alloc 2019; 17: 13. https://doi.org/10.1186/s12962-019-0180-9

  26. Betonico C, Titan S, Lira A, et al. Insulin glargineU100 improved glycemic control and reduced nocturnalhypoglycemia in patients with type 2 diabetesmellitus and chronic kidney disease stages 3 and 4.Clin Ther 2019; 41: 10. https://doi.org/10.1016/j.clinthera.2019.07.011




2020     |     www.medigraphic.com